↓ Skip to main content

An introduction to male breast cancer for urologists: epidemiology, diagnosis, principles of treatment, and special situations

Overview of attention for article published in International Brazilian Journal of Urology, October 2022
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (56th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 X users

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
39 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
An introduction to male breast cancer for urologists: epidemiology, diagnosis, principles of treatment, and special situations
Published in
International Brazilian Journal of Urology, October 2022
DOI 10.1590/s1677-5538.ibju.2021.0828
Pubmed ID
Authors

Fabiana Baroni Alves Makdissi, Silvana S. Santos, Almir Bitencourt, Fernando Augusto Batista Campos

Abstract

Breast cancer (BC) is mainly considered a disease in women, but male BC (MaBC) accounts for approximately 1.0% of BC diagnoses and 0.5% of malignant neoplasms in the western population. The stigmatization of MaBC, the fact that men are less likely to undergo regular health screenings, and the limited knowledge of health professionals about MaBC contribute to men being diagnosed at more advanced stages. The aim of this article is to increase the visibility of MaBC among urologists, who have more contact with male patients. This review highlights key points about the disease, the risk factors associated with MaBC, and the options for treatment. Obesity and increased population longevity are among the important risk factors for MaBC, but published studies have identified family history as extremely relevant in these patients and associated with a high penetrance at any age. There is currently no screening for MaBC in the general population, but the possibility of screening in men at high risk for developing BC can be considered. The treatment of MaBC is multidisciplinary, and, because of its rarity, there are no robust clinical studies evaluating the role of systemic therapies in the management of both localized and metastatic disease. Therefore, in current clinical practice, treatment strategies for men with breast cancer are extrapolated from information arising from studies in female patients.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 39 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 12 31%
Student > Bachelor 4 10%
Student > Master 2 5%
Lecturer > Senior Lecturer 1 3%
Student > Doctoral Student 1 3%
Other 3 8%
Unknown 16 41%
Readers by discipline Count As %
Unspecified 12 31%
Medicine and Dentistry 3 8%
Nursing and Health Professions 2 5%
Biochemistry, Genetics and Molecular Biology 2 5%
Veterinary Science and Veterinary Medicine 1 3%
Other 2 5%
Unknown 17 44%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 July 2023.
All research outputs
#14,925,951
of 25,392,582 outputs
Outputs from International Brazilian Journal of Urology
#288
of 726 outputs
Outputs of similar age
#186,054
of 439,259 outputs
Outputs of similar age from International Brazilian Journal of Urology
#4
of 7 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 726 research outputs from this source. They receive a mean Attention Score of 4.1. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 439,259 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.